Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection (DME, CRTH258B1401)
Latest Information Update: 19 Jul 2024
Price :
$35 *
At a glance
- Drugs Brolucizumab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 15 Jul 2024 Status changed from active, no longer recruiting to completed.
- 17 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2023 Planned End Date changed from 19 Jun 2026 to 29 Jun 2024.